Original Data

Paradoxical Negative HDL Cholesterol Response to Atorvastatin and Simvastatin Treatment in Chinese Type 2 Diabetic Patients

Yu-Hung Chang¹, Kun-Cheng Lin¹, Dao-Ming Chang¹, Chang-Hsun Hsieh², Lee Yau-Jiunn¹

Manuscript submitted January 22, 2013; resubmitted March 11, 2013; accepted May 20, 2013.

Keywords: high-density lipoprotein cholesterol, atorvastatin, simvastatin, lipid, type 2 diabetes

Abstract

OBJECTIVES: There is extensive but controversial evidence on the diverse effects of statins on the level of high-density lipoprotein cholesterol (HDL-C). Some of these effects may limit the benefits of statins in terms of cardiovascular risk reduction. To identify the conditions for beneficial effects, this study investigated the response to atorvastatin and simvastatin treatment in type 2 diabetic patients with elevated low-density lipoprotein cholesterol (LDL-C). METHODS: 2,872 subjects with type 2 diabetes from a disease management program were investigated. Patients with LDL-C ≥130 mg/dl or total cholesterol ≥200 mg/dl were put onto statin therapy by the National Health Insurance system in Taiwan. RESULTS: 1,080 patients who completed 1 year of statin treatment were analyzed. There were significant reductions in LDL-C in both the atorvastatin (37.1%) and simvastatin (34.3%) group after one year of treatment compared with baseline levels. Unexpectedly, the majority of diabetic patients who received atorvastatin or simvastatin did not show an increase in HDL-C levels. 59.8% of patients had a significant HDL-C reduction (ΔHDL-C ≤ -3%) after atorvastatin treatment. Multivariate logistic regression analysis showed that the following patients were at higher risk of HDL-C reduction after 12 months: (i) patients in whom statin therapy was initiated aged <65 years and who had a BMI ≥24 kg/m², (ii) male patients with a baseline HDL-C >40 mg/dl, and (iii) female patients with a baseline HDL-C >50 mg/dl. However, diabetic patients with severe atherogenic dyslipidemia (LDL-C ≥130, TG ≥204, and HDL-C ≤34 mg/dl) obtained more benefits in terms of HDL-C change after statin therapy. CONCLUSIONS: Diabetic patients, except those with severe atherogenic dyslipidemia, are prone to a decrease in serum HDL-C level after statin treatment, particularly after atorvastatin treatment.

Fulltext: HTML , PDF (219KB)

This article has been cited by other articles:

	The effect of simplified paired self-monitoring of blood glucose in patients with type 2 diabetes mellitus with persistent poor glycemic control Chang CJ, Chen SH, Lin KD, Hsu HC, Lee YJ, Chang YH Int J Clin Exp Med 2016. 9(3):6255-6262
	The effect of the Conversation Map program in patients with poor glycemic control with type 2 diabetes mellitus-when usual care is not enough Shih YT, Hsu HC, Chen SY, Hsieh CH, Wang RH, Lee YJ, Chang YH Int J Clin Exp Med 2016. 9(2):3473-3480
	Anti-hyperglycemic and hypolipidemic effects of baechukimchi with Ecklonia cava in type 2 diabetic db/db mice Lee HA, Park MH, Song YO, Jang MS, Han JS Food Sci Biotechnol 2015. 24(1):307-314
	Preliminary study on the efficacy and safety of atorvastatin in northern Han patients with acute ischemic cerebrovascular disease Zheng XD, Li XQ, Zhang JH, Xia C, Han YL, Chen HS Chin Med J 2015. 40(7):519-525
	Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis Chang YH, Lin KD, Shin SJ, Lee YJ Nutr Metab Cardiovasc Dis 2014. 24(10):1067-1073